Cell Penetrating Peptides as a Therapeutic Strategy in Chronic Lymphocytic Leukemia

被引:9
|
作者
Arrouss, Issam [1 ]
Decaudin, Didier [2 ,3 ]
Choquet, Sylvain [4 ]
Azar, Nabih [4 ]
Parizot, Christophe [5 ]
Zini, Jean M. [6 ]
Nemati, Fariba [3 ]
Rebollo, Angelita [1 ]
机构
[1] Univ Paris 06, INSERM, UMRS 945, F-75013 Paris, France
[2] Inst Curie, Dept Med Hematol, Paris, France
[3] Inst Curie, Translat Res Dept, Lab Preclin Invest, Paris, France
[4] Hop La Pitie Salpetriere, Serv Hematol Clin, Paris, France
[5] Hop La Pitie Salpetriere, AP HP, Dept Immunol Cellulaire & Tissulaire, Paris, France
[6] Hop St Louis, AP HP, Serv Hematol, Paris, France
关键词
apoptosis; Caspase-9; CLL; penetrating peptides; PP2A; APOPTOSIS; PROTEINS; SURVIVAL; PATHWAY; TARGET;
D O I
10.2174/0929866522666150216115352
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
PP2A is a serine/threonine phosphatase critical to a number of physiological and developmental processes. In this manuscript, we show that a peptide, specifically blocking the caspase9/PP2A interaction, DPT-C9h, induces apoptosis in primary tumour B cells isolated from peripheral blood mononuclear cells or bone marrow of chronic lymphocytic leukemia (CLL) patients, but not on B cells obtained from healthy donors (HD). Moreover, in both CLL patients and HD, DPT-C9h does not induce apoptosis on T-and NKcells and monocytes. Our results strongly suggest that DPT-C9h peptide has tumour specificity and that caspase-9/PP2Ac interaction constitutes a novel therapeutic approach for the treatment in CLL patients.
引用
收藏
页码:539 / 546
页数:8
相关论文
共 50 条
  • [21] A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor
    Burke, Russell T.
    Meadows, Sarah
    Loriaux, Marc M.
    Currie, Kevin S.
    Mitchell, Scott A.
    Maciejewski, Patricia
    Clarke, Astrid S.
    Dipaolo, Julie A.
    Druker, Brian J.
    Lannutti, Brian J.
    Spurgeon, Stephen E.
    ONCOTARGET, 2014, 5 (04) : 908 - 915
  • [22] Personalized Drug Analysis in B Cell Chronic Lymphocytic Leukemia Patients
    Liu, Guozhen
    Hu, Xiaoling
    Gao, Lei
    Feng, Zhenjun
    MEDICAL SCIENCE MONITOR, 2017, 23 : 2159 - 2167
  • [23] A new biology of cell penetrating peptides
    Howl, John
    Jones, Sarah
    PEPTIDE SCIENCE, 2021, 113 (01):
  • [24] Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia
    Merkel, Olaf
    Asslaber, Daniela
    Pinon, Josefina D.
    Egle, Alexander
    Greil, Richard
    CELL CYCLE, 2010, 9 (14) : 2764 - 2768
  • [25] Prognostic Value of Tie2-Expressing Monocytes in Chronic Lymphocytic Leukemia Patients
    Wos, Justyna
    Chocholska, Sylwia
    Kowalska, Wioleta
    Tomczak, Waldemar
    Szymanska, Agata
    Karczmarczyk, Agnieszka
    Szuster-Ciesielska, Agnieszka
    Wojciechowska, Agnieszka
    Bojarska-Junak, Agnieszka
    CANCERS, 2021, 13 (11)
  • [26] Recent advances in chronic lymphocytic leukemia
    Vyas, N.
    Hassan, A.
    INDIAN JOURNAL OF CANCER, 2012, 49 (01) : 137 - 143
  • [27] Extracellular vesicles in chronic lymphocytic leukemia
    Haderk, Franziska
    Hanna, Bola
    Richter, Karsten
    Schnoelzer, Martina
    Zenz, Thorsten
    Stilgenbauer, Stephan
    Lichter, Peter
    Seiffert, Martina
    LEUKEMIA & LYMPHOMA, 2013, 54 (08) : 1826 - 1830
  • [28] Chronic lymphocytic leukemia
    Gauthier, M.
    REVUE DE MEDECINE INTERNE, 2022, 43 (06): : 356 - 364
  • [29] Chronic lymphocytic leukemia
    Al-Sawaf, Othman
    Eichhorst, Barbara
    Hallek, Michael
    ONKOLOGE, 2020, 26 (05): : 465 - 476
  • [30] Chronic lymphocytic leukemia
    Al-Sawaf, Othman
    Eichhorst, Barbara
    Hallek, Michael
    INTERNIST, 2020, 61 (03): : 277 - 287